We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

JRVR:NASDAQJames River Group Holdings, Inc. Analysis

Data as of 2026-05-26 - not real-time

$3.98

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

James River Group is trading well below its long‑term intrinsic value, with the market price far trailing the discounted cash‑flow estimate. The 20‑day simple moving average sits beneath the 50‑day average, confirming a bearish price trend, while the 14‑day RSI is deep in oversold territory, suggesting potential short‑term price support. The MACD histogram remains negative, reinforcing bearish momentum, and volume has been on a downward trajectory, indicating waning buying interest. Recent earnings disclosed a sizable reinstatement premium expense that pushed the combined ratio above 100 %, highlighting a one‑off hit to profitability. Despite the setback, the company still generates positive operating cash flow and a modest free‑cash‑flow surplus, underpinning its dividend capability. The current price hovers just above the identified support level, leaving limited downside but also room for a technical bounce.
From a valuation perspective, the stock appears markedly undervalued relative to peers, with a price‑to‑earnings multiple well under the industry average and a price‑to‑book ratio below one. The dividend yield, though modest, is supported by a low payout ratio and ample cash balances, making the payout sustainable. Volatility is elevated and the beta is low, reflecting a stock that moves sharply but is less correlated with broader market swings. Regulatory and geographic exposures are limited to the U.S. specialty insurance market, reducing those specific risk dimensions. Overall, the fundamentals suggest a value‑oriented opportunity, while the technical picture remains cautious, implying a wait‑and‑see stance for short‑term traders.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bearish technical indicators but price near support
  • Oversold RSI indicating possible short‑term rebound
  • Recent earnings hit from reinstatement premium

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Significant undervaluation versus DCF fair value
  • Sustainable dividend with low payout ratio
  • Improving profitability metrics once one‑off charges normalize

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Strong value proposition in niche specialty insurance
  • Consistent cash generation supporting dividend continuity
  • Low beta and limited regulatory/geographic exposure

Key Metrics & Analysis

Financial Health

Revenue Growth-12.10%
Profit Margin4.34%
P/E Ratio9.5
ROE4.74%
ROA0.61%
Debt/Equity50.63
P/B Ratio0.3
Op. Cash Flow$32.0M
Free Cash Flow$215.6M
Industry P/E16.7

Technical Analysis

TrendBearish
RSI25.5
Support$3.76
Resistance$6.42
MA 20$4.70
MA 50$5.65
MA 200$5.91
MACDBearish
VolumeDecreasing
Fear & Greed Index91.05

Valuation

Fair Value$58.48
Target Price$5.38
Upside/Downside35.05%
GradeUndervalued
TypeValue
Dividend Yield1.00%

Risk Assessment

Beta0.20
Volatility87.22%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.